• Glucagon-like peptide 1 receptor agonists (GLP-1) (medicines used to lower blood glucose) probably reduce the risk of death due to any cause but may have little or no death due to a heart attack in ...

Scientists have discovered an antibody treatment that may help prevent both muscle loss and bone density loss in people using ...

Scientists discovered years ago that the hypothalamus—which helps to manage body temperature, hunger, sex drive, sleep and ...

Scientists discovered years ago that the hypothalamus - which helps to manage body temperature, hunger, sex drive, sleep and more - includes neurons that express the protein opsin 3 (OPN3).

Researchers at Brown University and Cincinnati Children’s found that suppressing opsin 3 in the brain of mice makes them eat ...

Palatin Technologies, Inc. (AMEX: PTN) Q2 2025 Earnings Call Transcript February 13, 2025 ...

Phase 2 obesity co-administration study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatide Database lock completed Topline data readout ...

ANI Pharmaceuticals offers an asymmetric opportunity in small-cap pharma, with a niche in generics, rare disease treatments, ...

Palatin Technologies (NYSEAMERICAN:PTN – Get Free Report) will likely be announcing its earnings results before the market ...

Inc. (NYSE American: PTN), a biopharmaceutical firm with a market capitalization of $23.22 million, has announced a new funding round through a registered direct offering and a concurrent private ...

Palatin Technologies, Inc. ("Palatin" or the "Company"), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor ...

"Palatin concludes Phase II trial of combination therapy for obesity" was originally created and published by Clinical Trials ...